Navigation Links
Novel Technology Breaks Through Cancer Pain
Date:8/19/2007

MORRISVILLE, N.C., Aug. 16 /PRNewswire/ -- Cancer patients fraught with flare-ups of pain, or breakthrough pain, may soon receive some assistance in the form of a new easy-to-use oral drug delivery system developed by BioDelivery Sciences designed to quickly deliver pain medication.

Cancer patients frequently experience two types of pain: persistent and breakthrough. Persistent cancer pain is characterized as continuous pain present for long periods of time, and often most of the day. Persistent pain is treated by daily or regular doses of pain medication.

Breakthrough pain is a brief and often severe shooting of pain that "breaks through" a patient's continuous medication for persistent pain. Breakthrough pain often has a rapid onset and lasts a short duration of time. It is called breakthrough pain because it "breaks through" a regular pain medicine schedule.

"Breakthrough pain is caused either by the cancer itself or the cancer treatment. For some patients, the pain is connected to certain activities, such as walking or dressing. For others, it occurs unexpectedly," says Dr. Andrew Finn, BioDelivery Sciences' VP of Product Development.

One breakthrough pain medication is the opiate fentanyl. Fentanyl is a potent opioid analgesic (painkiller) first developed in the 1950s, and long in use by the medical community for controlling various types of pain.

The next generation product able to quickly deliver fentanyl for the treatment of cancer breakthrough pain is a patient-friendly, small oral adhesive disc called BEMA Fentanyl, which has recently completed Phase III trials by BioDelivery Sciences. The BEMA technology is a very small layered disc that is applied to a mucosal surface (inner lining of the mouth) in a similar way a transdermal disc is applied to the skin.

The small disc is composed of an adhesive layer and a non-adhesive backing layer. The disc adheres to the inside cheeks and delivers the dose of medication quickly into the bloodstream. Instead of requiring removal upon completion of the drug delivery, the BEMA disc disintegrates in the mouth and leaves no drug residue.

The results of the Phase III pivotal efficacy clinical trial in cancer patients with breakthrough pain announced earlier this year with BEMA Fentanyl are very encouraging.

"The results of our study demonstrated that fentanyl could be delivered rapidly, effectively and easily using the BEMA technology," said Finn. "Besides allowing greater absorption of fentanyl, the BEMA disc was easier to use, as it only required seconds to apply."

It is estimated that at least 60 percent of people with advanced cancer will experience significant pain of some type, oftentimes including breakthrough pain. For more information on BEMA Fentanyl, log on to http://www.bdsinternational.com/


'/>"/>
SOURCE BioDelivery Sciences

Copyright©2007 PR Newswire.

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ Cartilage ... Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - Forecast ... USD 779.8 Million by 2021 from USD 414.6 Million in 2016, ... 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health ... Distinction, recognizing the organization as a top behavioral service provider in the country. ... clinical quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... EHS audit protocols to understand the scope of their EHS regulatory obligations and ...
Breaking Medicine News(10 mins):